Small molecule tolfenamic acid inhibits PC-3 cell proliferation and invasion in vitro, and tumor growth in orthotopic mouse model for prostate cancer

Prostate

Volumn 72, Issue 15, 2012, Pages 1648-1658

  Sankpal, Umesh T ^a   Abdelrahim, Maen ^a,b   Connelly, Sarah F ^a   Lee, Chris M ^a   Madero Visbal, Rafael ^a   Colon, Jimmie ^a   Smith, Joshua ^a   Safe, Stephen ^c   Maliakal, Pius ^a   Basha, Riyaz ^a  

^a M D ANDERSON CANCER CENTER ORLANDO   (United States)

^b TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

^c TEXAS A AND M UNIVERSITY   (United States)

Author keywords

cell invasion; Sp1; survivin; tolfenamic acid; transcription factors

Indexed keywords

CASPASE; CORN OIL; CYCLIN D3; CYCLIN DEPENDENT KINASE 1; CYCLIN DEPENDENT KINASE 4; DIMETHYL SULFOXIDE; LIPOCORTIN 5; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN KINASE B; SCATTER FACTOR RECEPTOR; SURVIVIN; TOLFENAMIC ACID; TRANSCRIPTION FACTOR E2F1; TRANSCRIPTION FACTOR SP1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BOYDEN CHAMBER ASSAY; CANCER CELL CULTURE; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL INVASION; CELL LYSATE; CELL PROLIFERATION; CELL STRAIN; CELL VIABILITY; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DRUG EFFICACY; DRUG INHIBITION; ENZYME ACTIVITY; FLOW CYTOMETRY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOASSAY; IMMUNOHISTOCHEMISTRY; IN VITRO GENE TRANSFER; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; STAINING; TISSUE SECTION; TUMOR GROWTH; TUMOR VOLUME; TUMOR XENOGRAFT; WESTERN BLOTTING; WHOLE CELL;

ADENOCARCINOMA; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL ADHESION; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; MALE; MICE; MICE, NUDE; NEOPLASM INVASIVENESS; ORTHO-AMINOBENZOATES; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84867064767     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.22518     Document Type: Article

References (70)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ,. Cancer statistics, 2008. CA Cancer J Clin 2008; 58 (2): 71-96.
2. Strom SS, Yamamura Y, Duphorne CM, Spitz MR, Babaian RJ, Pillow PC, Hursting SD,. Phytoestrogen intake and prostate cancer: A case-control study using a new database. Nutr Cancer 1999; 33 (1): 20-25.
3. Lee AH, Fraser ML, Meng X, Binns CW,. Protective effects of green tea against prostate cancer. Expert Rev Anticancer Ther 2006; 6 (4): 507-513.
4. Steiner MS, Pound CR,. Phase IIA clinical trial to test the efficacy and safety of Toremifene in men with high-grade prostatic intraepithelial neoplasia. Clin Prostate Cancer 2003; 2 (1): 24-31.
5. Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, Lieber MM, Cespedes RD, Atkins JN, Lippman SM, Carlin SM, Ryan A, Szczepanek CM, Crowley JJ, Coltman CA Jr., The influence of finasteride on the development of prostate cancer. N Engl J Med 2003; 349 (3): 215-224.
6. Andriole GL, Roehrborn C, Schulman C, Slawin KM, Somerville M, Rittmaster RS,. Effect of dutasteride on the detection of prostate cancer in men with benign prostatic hyperplasia. Urology 2004; 64 (3): 537-541; discussion 542-543.
7. Price D, Stein B, Sieber P, Tutrone R, Bailen J, Goluboff E, Burzon D, Bostwick D, Steiner M,. Toremifene for the prevention of prostate cancer in men with high grade prostatic intraepithelial neoplasia: Results of a double-blind, placebo controlled, phase IIB clinical trial. J Urol 2006; 176 (3): 965-970; discussion 970-971.
8. Singer EA, Palapattu GS, van Wijngaarden E,. Prostate-specific antigen levels in relation to consumption of nonsteroidal anti-inflammatory drugs and acetaminophen: Results from the 2001-2002 National Health and Nutrition Examination Survey. Cancer 2008; 113 (8): 2053-2057.
9. Moreno J, Krishnan AV, Swami S, Nonn L, Peehl DM, Feldman D,. Regulation of prostaglandin metabolism by calcitriol attenuates growth stimulation in prostate cancer cells. Cancer Res 2005; 65 (17): 7917-7925.
10. Krishnan AV, Srinivas S, Feldman D,. Inhibition of prostaglandin synthesis and actions contributes to the beneficial effects of calcitriol in prostate cancer. Dermatoendocrinology 2009; 1 (1): 7-11.
11. Dubois RN, Abramson SB, Crofford L, Gupta RA, Simon LS, Van De Putte LB, Lipsky PE,. Cyclooxygenase in biology and disease. Faseb J 1998; 12 (12): 1063-1073.
12. Williams CS, Mann M, DuBois RN,. The role of cyclooxygenases in inflammation, cancer, and development. Oncogene 1999; 18 (55): 7908-7916.
13. Elwood PC, Gallagher AM, Duthie GG, Mur LA, Morgan G,. Aspirin, salicylates, and cancer. Lancet 2009; 373 (9671): 1301-1309.
14. Cuzick J, Otto F, Baron JA, Brown PH, Burn J, Greenwald P, Jankowski J, La Vecchia C, Meyskens F, Senn HJ, Thun M,. Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: An international consensus statement. Lancet Oncol 2009; 10 (5): 501-507.
15. Vane JR,. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 1971; 231 (25): 232-235.
16. Jacoby RF, Seibert K, Cole CE, Kelloff G, Lubet RA,. The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis. Cancer Res 2000; 60 (18): 5040-5044.
17. Reddy BS, Hirose Y, Lubet R, Steele V, Kelloff G, Paulson S, Seibert K, Rao CV,. Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis. Cancer Res 2000; 60 (2): 293-297.
18. Boolbol SK, Dannenberg AJ, Chadburn A, Martucci C, Guo XJ, Ramonetti JT, Abreu-Goris M, Newmark HL, Lipkin ML, DeCosse JJ, Bertagnolli MM,. Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis. Cancer Res 1996; 56 (11): 2556-2560.
19. Chiu CH, McEntee MF, Whelan J,. Sulindac causes rapid regression of preexisting tumors in Min/+ mice independent of prostaglandin biosynthesis. Cancer Res 1997; 57 (19): 4267-4273.
20. Tarnawski AS, Jones MK,. Inhibition of angiogenesis by NSAIDs: Molecular mechanisms and clinical implications. J Mol Med (Berlin, Germany) 2003; 81 (10): 627-636.
21. Taketo MM,. Cyclooxygenase-2 inhibitors in tumorigenesis (Part I). J Natl Cancer Inst 1998; 90 (20): 1529-1536.
22. Taketo MM,. Cyclooxygenase-2 inhibitors in tumorigenesis (Part II). J Natl Cancer Inst 1998; 90 (21): 1609-1620.
23. Gately S, Li WW,. Multiple roles of COX-2 in tumor angiogenesis: A target for antiangiogenic therapy. Semin Oncol 2004; 31 (2 Suppl. 7) 2-11.
24. Lincova E, Hampl A, Pernicova Z, Starsichova A, Krcmar P, Machala M, Kozubik A, Soucek K,. Multiple defects in negative regulation of the PKB/Akt pathway sensitise human cancer cells to the antiproliferative effect of non-steroidal anti-inflammatory drugs. Biochem pharmacol 2009; 78 (6): 561-572.
25. Abdelrahim M, Baker CH, Abbruzzese JL, Safe S,. Tolfenamic acid and pancreatic cancer growth, angiogenesis, and Sp protein degradation. J Natl Cancer Inst 2006; 98 (12): 855-868.
26. Colon J, Basha MR, Madero-Visbal R, Konduri S, Baker CH, Herrera LJ, Safe S, Sheikh-Hamad D, Abudayyeh A, Alvarado B, Abdelrahim M,. Tolfenamic acid decreases c-Met expression through Sp proteins degradation and inhibits lung cancer cells growth and tumor formation in orthotopic mice. Invest New Drugs 2011; 29 (1): 41-51.
27. Konduri S, Colon J, Baker CH, Safe S, Abbruzzese JL, Abudayyeh A, Basha MR, Abdelrahim M,. Tolfenamic acid enhances pancreatic cancer cell and tumor response to radiation therapy by inhibiting survivin protein expression. Mol Cancer Ther 2009; 8 (3): 533-542.
28. Papineni S, Chintharlapalli S, Abdelrahim M, Lee SO, Burghardt R, Abudayyeh A, Baker C, Herrera L, Safe S,. Tolfenamic acid inhibits esophageal cancer through repression of specificity proteins and c-Met. Carcinogenesis 2009; 30 (7): 1193-1201.
29. Andersen KV, Larsen S, Alhede B, Gelting N, Buchardt O,. Characterization of two polymorphic forms of tolfenamic acid, N-(2-methyl-3-chlorophenyl) anthranilic acid: Their crystal structures and relative stabilities. J Chem Soc, Perkin Trans 1989; 2: 1443-1447.
30. Basha R, Baker CH, Sankpal UT, Ahmad S, Safe S, Abbruzzese JL, Abdelrahim M,. Therapeutic applications of NSAIDS in cancer: Special emphasis on tolfenamic acid. Front Biosci (Schol Ed) 2011; 3: 797-805.
31. Eskerod O,. Gastrointestinal tolerance studies on tolfenamic acid in humans and animals. Pharmacol Toxicol 1994; 75 (Suppl. 2): 44-48.
32. Black AR, Black JD, Azizkhan-Clifford J,. Sp1 and kruppel-like factor family of transcription factors in cell growth regulation and cancer. J Cell Physiol 2001; 188 (2): 143-160.
33. Bouwman P, Philipsen S,. Regulation of the activity of Sp1-related transcription factors. Mol Cell Endocrinol 2002; 195 (1-2): 27-38.
34. Safe S, Kim K,. Nuclear receptor-mediated transactivation through interaction with Sp proteins. Prog Nucleic Acid Res Mol Biol 2004; 77: 1-36.
35. Shi Q, Le X, Abbruzzese JL, Peng Z, Qian CN, Tang H, Xiong Q, Wang B, Li XC, Xie K,. Constitutive Sp1 activity is essential for differential constitutive expression of vascular endothelial growth factor in human pancreatic adenocarcinoma. Cancer Res 2001; 61 (10): 4143-4154.
36. Wang L, Wei D, Huang S, Peng Z, Le X, Wu TT, Yao J, Ajani J, Xie K,. Transcription factor Sp1 expression is a significant predictor of survival in human gastric cancer. Clin Cancer Res 2003; 9 (17): 6371-6380.
37. Yao JC, Wang L, Wei D, Gong W, Hassan M, Wu TT, Mansfield P, Ajani J, Xie K,. Association between expression of transcription factor Sp1 and increased vascular endothelial growth factor expression, advanced stage, and poor survival in patients with resected gastric cancer. Clin Cancer Res 2004; 10 (12 Pt 1): 4109-4117.
38. Shin T, Sumiyoshi H, Matsuo N, Satoh F, Nomura Y, Mimata H, Yoshioka H,. Sp1 and Sp3 transcription factors upregulate the proximal promoter of the human prostate-specific antigen gene in prostate cancer cells. Arch Biochem Biophys 2005; 435 (2): 291-302.
39. Humphrey PA, Zhu X, Zarnegar R, Swanson PE, Ratliff TL, Vollmer RT, Day ML,. Hepatocyte growth factor and its receptor (c-MET) in prostatic carcinoma. Am J Pathol 1995; 147 (2): 386-396.
40. Basha R, Ingersoll SB, Sankpal UT, Ahmad S, Baker CH, Edwards JR, Holloway RW, Kaja S, Abdelrahim M,. Tolfenamic acid inhibits ovarian cancer cell growth and decreases the expression of c-Met and survivin through suppressing specificity protein transcription factors. Gynecol Oncol 2011; 122 (1): 163-170.
41. Partridge J, Flaherty P,. An in vitro FluoroBlok tumor invasion assay. J Vis Exp 2009; (29).
42. Kovar JL, Johnson MA, Volcheck WM, Chen J, Simpson MA,. Hyaluronidase expression induces prostate tumor metastasis in an orthotopic mouse model. Am J Pathol 2006; 169 (4): 1415-1426.
43. Pettaway CA, Pathak S, Greene G, Ramirez E, Wilson MR, Killion JJ, Fidler IJ,. Selection of highly metastatic variants of different human prostatic carcinomas using orthotopic implantation in nude mice. Clin Cancer Res 1996; 2 (9): 1627-1636.
44. Rembrink K, Romijn JC, van der Kwast TH, Rubben H, Schroder FH,. Orthotopic implantation of human prostate cancer cell lines: A clinically relevant animal model for metastatic prostate cancer. Prostate 1997; 31 (3): 168-174.
45. Maliakal P, Abdelrahim M, Sankpal UT, Maliakal C, Baker CH, Safe S, Herrera LJ, Abudayyeh A, Kaja S, Basha R,. Chemopreventive effects of tolfenamic acid against esophageal tumorigenesis in rats. Invest New Drugs 2011; [Epub ahead of print].
46. Sankpal UT, Goodison S, Abdelrahim M, Basha R,. Targeting SP1 transcription factor in prostate cancer therapy. Med Chem 2011; 7 (5): 518-525.
47. Molinari M,. Cell cycle checkpoints and their inactivation in human cancer. Cell Prolif 2000; 33 (5): 261-274.
48. Grossmann ME, Huang H, Tindall DJ,. Androgen receptor signaling in androgen-refractory prostate cancer. J Natl Cancer Inst 2001; 93 (22): 1687-1697.
49. Knudsen BS, Edlund M,. Prostate cancer and the met hepatocyte growth factor receptor. Adv Cancer Res 2004; 91: 31-67.
50. Roberts AB, Wakefield LM,. The two faces of transforming growth factor beta in carcinogenesis. Proc Natl Acad Sci USA 2003; 100 (15): 8621-8623.
51. Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF,. Met, metastasis, motility and more. Nat Rev Mol Cell Biol 2003; 4 (12): 915-925.
52. Altieri DC,. Survivin, versatile modulation of cell division and apoptosis in cancer. Oncogene 2003; 22 (53): 8581-8589.
53. Altieri DC, Marchisio PC,. Survivin apoptosis: An interloper between cell death and cell proliferation in cancer. Lab Investig 1999; 79 (11): 1327-1333.
54. Altieri DC,. The molecular basis and potential role of survivin in cancer diagnosis and therapy. Trends Mol Med 2001; 7 (12): 542-547.
55. Nakahara T, Takeuchi M, Kinoyama I, Minematsu T, Shirasuna K, Matsuhisa A, Kita A, Tominaga F, Yamanaka K, Kudoh M, Sasamata M,. YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts. Cancer Res 2007; 67 (17): 8014-8021.
56. Kishi H, Igawa M, Kikuno N, Yoshino T, Urakami S, Shiina H,. Expression of the survivin gene in prostate cancer: Correlation with clinicopathological characteristics, proliferative activity and apoptosis. J Urol 2004; 171 (5): 1855-1860.
57. Li Y, Xie M, Yang J, Yang D, Deng R, Wan Y, Yan B,. The expression of antiapoptotic protein survivin is transcriptionally upregulated by DEC1 primarily through multiple sp1 binding sites in the proximal promoter. Oncogene 2006; 25 (23): 3296-3306.
58. Xu R, Zhang P, Huang J, Ge S, Lu J, Qian G,. Sp1 and Sp3 regulate basal transcription of the survivin gene. Biochem Biophys Res Commun 2007; 356 (1): 286-292.
59. Verras M, Lee J, Xue H, Li TH, Wang Y, Sun Z,. The androgen receptor negatively regulates the expression of c-Met: Implications for a novel mechanism of prostate cancer progression. Cancer Res 2007; 67 (3): 967-975.
60. Fresno Vara JA, Casado E, de Castro J, Cejas P, Belda-Iniesta C, Gonzalez-Baron M,. PI3K/Akt signalling pathway and cancer. Cancer Treat Rev 2004; 30 (2): 193-204.
61. Cai T, Nesi G, Tinacci G, Giubilei G, Gavazzi A, Mondaini N, Zini E, Bartoletti R,. Clinical importance of lymph node density in predicting outcome of prostate cancer patients. J Surg Res 2011; 167 (2): 267-272.
62. Loberg RD, Logothetis CJ, Keller ET, Pienta KJ,. Pathogenesis and treatment of prostate cancer bone metastases: Targeting the lethal phenotype. J Clin Oncol 2005; 23 (32): 8232-8241.
63. Steeg PS, Theodorescu D,. Metastasis: A therapeutic target for cancer. Nat Clin Pract Oncol 2008; 5 (4): 206-219.
64. Deryugina EI, Quigley JP,. Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev 2006; 25 (1): 9-34.
65. Sounni NE, Noel A,. Membrane type-matrix metalloproteinases and tumor progression. Biochimie 2005; 87 (3-4): 329-342.
66. Guan H, Cai J, Zhang N, Wu J, Yuan J, Li J, Li M,. Sp1 is upregulated in human glioma, promotes MMP-2-mediated cell invasion and predicts poor clinical outcome. Int J Cancer 2012; 130 (3): 593-601.
67. Hung WC, Chang HC,. Indole-3-carbinol inhibits Sp1-induced matrix metalloproteinase-2 expression to attenuate migration and invasion of breast cancer cells. J Agric Food Chem 2009; 57 (1): 76-82.
68. Seznec J, Silkenstedt B, Naumann U,. Therapeutic effects of the Sp1 inhibitor mithramycin A in glioblastoma. J Neurooncol 2011; 101 (3): 365-377.
69. Sroka IC, Nagle RB, Bowden GT,. Membrane-type 1 matrix metalloproteinase is regulated by sp1 through the differential activation of AKT, JNK, and ERK pathways in human prostate tumor cells. Neoplasia 2007; 9 (5): 406-417.
70. Pan MR, Hung WC,. Nonsteroidal anti-inflammatory drugs inhibit matrix metalloproteinase-2 via suppression of the ERK/Sp1-mediated transcription. J Biol Chem 2002; 277 (36): 32775-32780.